In addition to prostate-specific antigen doubling time (PSADT), which has been shown to be a predictor of PC progression, metastases, and PC-specific mortality (PCSM), novel prognostic markers are needed to improve risk stratification and guide more personalized treatment decisions [6]. This evidence concerns the gene KLK3 and pachyonychia congenita.